![Avizohar Argov](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Avizohar Argov
Corporate Officer/Principal en The Hebrew University Hadassah Medical School .
Cargos activos de Avizohar Argov
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
The Hebrew University Hadassah Medical School | Corporate Officer/Principal | - | - |
Historial de carrera de Avizohar Argov
Antiguos cargos conocidos de Avizohar Argov.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Director Técnico/Científico/I+D | 01/06/2014 | - |
Estadísticas
Internacional
Israel | 3 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Bolsa de valores
- Insiders
- Avizohar Argov
- Experiencia